Clinical trials: Lipid Metabolism Disorders
Hyperlipidemia
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are…
- Trial name
- SPIRE-SI (NCT02135029)
- Testing
- Bococizumab (PF-04950615;RN316), Atorvastatin
- Where
- 40 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- Pfizer
Dyslipidaemia
A Study of AZD8233 in Participants With Dyslipidemia
AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study aims to evaluate the dose-dependent reduction in LDL-C after SC administration of multiple doses of AZD8233 as well as the associated…
- Trial name
- NCT04641299
- Testing
- AZD8233
- Where
- 19 sites in United States, Denmark and 1 more
- Volunteers
- 119 people
- Sponsor
- AstraZeneca
Multiple Sclerosis
Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis
The association of Multiple Sclerosis (MS) and Fabry disease is known from own clinical experiences as well as from case reports in the literature, where symptoms and suspicious results in the brain MRI led to the misdiagnosis of…
- Trial name
- NCT01271699
- Volunteers
- 250 people
- Sponsor
- CENTOGENE GmbH Rostock
Dyslipidemias
Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex Treatment
This study is a large-scale, prospective, multi-site, and non-interventional observational study to observe the change and safety of dyslipidemia management status when administering statin+etimib complex drugs in patients with…
- Trial name
- NCT05614765
- Testing
- Statin+Ezetimibe compound
- Where
- South Korea
- Volunteers
- 18,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Dyslipidemias, High Cholesterol
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hypercholesterolemia…
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia
- Trial name
- BROOKLYN (NCT05425745)
- Testing
- Obicetrapib
- Where
- 96 sites in United States, Canada and 8 more
- Volunteers
- 354 people
- Sponsor
- NewAmsterdam Pharma
Healthy
Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fed Conditions
The purpose of this study is to compare the rate and extent of absorption of terbinafine hydrochloride 250 mg tablets versus Lamisil® 250 mg tablets administered as 1 x 250 mg tablet under fed conditions.
- Trial name
- NCT01286701
- Testing
- Terbinafine Hydrochloride Tablets, 250 mg
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Homozygous Familial Hypercholesterolemia
Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3- LRX for reduction of low density lipoprotein cholesterol (LDL-C) levels in patients with Homozygous Familial Hypercholesterolemia (HoFH).
- Trial name
- NCT03455777
- Testing
- AKCEA-ANGPTL3-LRX
- Where
- Canada
- Sponsor
- Akcea Therapeutics
Hypertension, Hypercholesterolemia
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
This study will assess and compare the efficacy and safety of valsartan and the combination of valsartan and simvastatin in patients with high blood pressure and high cholesterol.
- Conditions
- Hypertension, Hypercholesterolemia, Dyslipidemia
- Trial name
- NCT00385931
- Testing
- Valsartan and simvastatin
- Where
- United States
- Volunteers
- 412 people
- Sponsor
- Novartis
Dyslipidemia
Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers
This study is a randomized, open-label, single arm, multi-dose, crossover study to evaluate drug-drug interaction and safety after co-administration of D352 and D794 in healthy adult volunteers.
- Trial name
- NCT06758661
- Testing
- D352, D794
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in patients with stable coronary heart disease…
- Trial name
- NCT01516541
- Testing
- Background care, dalcetrapib
- Where
- 241 sites in United States, Australia and 11 more
- Volunteers
- 2,220 people
- Sponsor
- Hoffmann-La Roche
Pregnancy, Hyperlipidemias
Bempedoic Acid Pregnancy Surveillance Program
Bempedoic acid pregnancy surveillance program
- Trial name
- NCT05103254
- Testing
- Bempedoic Acid, Bempedoic Acid / Ezetimibe
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Esperion Therapeutics, Inc.
Hypercholesterolemia
Open Label Study of Long Term Safety Evaluation of Alirocumab
Primary Objective: To assess the long-term safety of alirocumab (SAR236553/REGN727) when added to lipid-lowering therapy in participants with heterozygous familial hypercholesterolemia (heFH) who had completed EFC12492…
- Trial name
- ODYSSEY OLE (NCT01954394)
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 177 sites in United States, Argentina and 22 more
- Volunteers
- 986 people
- Sponsor
- Sanofi
Hypertension and Dyslipidemia
A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia
The primary objective of this study is to evaluate the effectiveness of a combination drug containing fimasartan and statins on the control of hypertension and dyslipidemia, and the secondary objective is to evaluate the drug…
- Trial name
- FIMASTAR (NCT04554953)
- Testing
- Combination drug containing fimasartan and statins
- Where
- South Korea
- Volunteers
- 10,877 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Fabry Disease
A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.
This is an international, non-interventional research study of adult patients with Fabry Disease and their caregivers. The study comprised a prospective time and motion evaluation and a cross-sectional evaluation of patient and…
- Trial name
- NCT04281537
- Testing
- Enzyme Replacement Therapy (ERT)
- Where
- 9 sites in United States, Brazil and 3 more
- Volunteers
- 82 people
- Sponsor
- Amicus Therapeutics
Hypercholesterolemia
Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia
This study is designed to measure the effects of LGT209 when given intravenously to patients with high cholesterol who are on stable doses of statin medications, and to healthy subjects with elevated cholesterol
- Trial name
- NCT01979601
- Testing
- LGT209
- Where
- 2 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Myopathy
DNA Diagnostic System for Statin Safety and Efficacy
Lipitor®, Zocor®, and Crestor® are statin drugs commonly taken to lower cholesterol and prevent heart disease. Statins lower cholesterol by different amounts in different patients and sometimes statins cause muscle pain, cramps…
- Trial name
- SIM (NCT00767130)
- Where
- 3 sites in United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Genomas, Inc
Dyslipidemias
A Clinical Pharmacology Study of K-877 Controlled Release Tablet
A study to compare the efficacy, safety, and pharmacokinetics of K-877 controlled release tablets with a current normal K-877 tablet in dyslipidemia.
- Trial name
- NCT04079530
- Testing
- K-877 IR 0.2 mg/day, K-877 CR 0.4 mg/day, K-877 CR 0.8 mg/day
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Kowa Company, Ltd.
Hypercholesterolemia
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
The main objectives of this study are to evaluate the efficacy and safety of combination therapy BMS-201038 (AEGR-733) plus ezetimibe vs. each agent given alone on LDL cholesterol and other lipoproteins over 12 weeks of therapy.
- Trial name
- NCT00405067
- Testing
- BMS-201038 (AEGR-733), Ezetimibe
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Lipid Metabolism Disorders, Cardiovascular Diseases
Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD
Retrospective observational study of the efficacy and safety of statin monotherapy or statins in combination with ezetimibe in patients receiving lipid-lowering therapy in both primary and secondary prevention of cardiovascular…
- Trial name
- UNISON (NCT04895098)
- Testing
- statin and ezetimibe combination therapy, statin monotherapy
- Where
- 31 sites in Russia
- Volunteers
- 1,000 people
- Sponsor
- Akrikhin
Hypercholesterolemia
A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)
The purpose of this study is to investigate the effect of an investigational cholesterol-lowering drug in patients who are currently taking an approved medication for hypercholesterolemia (high cholesterol levels) and have been…
- Trial name
- NCT00132717
- Testing
- MK0653A (ezetimibe [+] simvastatin), Comparator: atorvastatin, Comparator: fluvastatin
- Volunteers
- 450 people
- Sponsor
- Organon and Co
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.